Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049243 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
A Phase 4 study of Atopic Dermatitis, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01049243 is a Phase 4 study of Atopic Dermatitis that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01049243, a Phase 4 study of Atopic Dermatitis, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.
Conditions Studied
Interventions
- DRUG Fluocinonide Cream 0.1%
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049243
The ClinicalTrials.gov registry entry for NCT01049243 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Fluocinonide Cream 0.1% is the first listed.
NCT01049243 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01049243 about?
NCT01049243 is a clinical study titled "A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis". The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.
What is the current status of trial NCT01049243?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2009-03. Estimated completion is 2009-10.
What conditions does trial NCT01049243 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT01049243?
The interventions under investigation include: Fluocinonide Cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT01049243?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049243 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.